Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + bevacizumab + SOX chemotherapy for first-line treatment of gastric cancer with liver metastasis
ChiCTR2500101259Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoint: Objective Response Rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2500101259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101259.